Compare AbbVie Inc (ABBV) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Petróleo Brasileiro SA — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Petróleo Brasileiro SA trades at $17.16 (market cap $102.10B). The key difference: AbbVie Inc is far larger — about 4.4× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (10.58%). Which is the better fit depends on your goals.
| ABBV | PBR | |
|---|---|---|
Market Cap | $449.91B | $102.10B |
Sector | Health | Technology |
52-Week High | $261.07 | $22.03 |
52-Week Low | $184.85 | $11.54 |
Enterprise Value | $513.38B | $164.64B |
Dividend Yield | 2.72% | 10.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.
Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.
PBR trades at $16.26, up 0.93% with a bearish technical outlook despite strong fundamentals. The company reported $488.72B revenue and $107.58B net income for 2025, with attractive valuation metrics including a 5.18 P/E ratio and 24.94% ROE. Recent earnings showed mixed results with a Q1 2026 miss but strong beats in previous quarters. Analyst consensus remains positive with a $23.90 price target, while technical indicators show bearish momentum with key support at $16.
PBR presents a compelling value opportunity with deep discount valuation and robust cash flow generation supporting substantial dividends. However, recent earnings volatility and bearish technical signals suggest near-term pressure. The stock's 46% upside to consensus target offers significant potential, but investors should monitor execution on production growth targets and global oil price stability as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
